3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
17
Rectal Neoplasms
9
Triple Negative Breast Neoplasms
7
Stomach Neoplasms
7
Colorectal Neoplasms
6
Adenocarcinoma
6
Neoplasm Metastasis
5
Esophageal Neoplasms
5
Adenocarcinoma Of Esophagus
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Pancreatic Neoplasms
4
Nasopharyngeal Carcinoma
4
Neoplasms
3
Esophageal Squamous Cell Carcinoma
2
Carcinoma
2
Biliary Tract Neoplasms
2
Advanced Solid Tumour
2
Solid Tumors
1
Pancreatic Ductal Adenocarcinoma
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Locally Advanced Gastric Cancer
1
HIV Infections
1
HER2-positive Gastric Cancer
1
HER2-positive Breast Cancer
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Colorectal Cancer Metastatic
1
Colonic Neoplasms
1
Interventions
11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Capecitabine
×
30 days
×
Clear all
No trials found.